Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PGK1 | P00558 | 1/20 | 0.38 |
| ▸ | GART | P22102 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL428455 | 0.87 | HCAR3 (0.53) | HCAR3LMNAMAPTL3MBTL1MAPK1 | |
| SCHEMBL26791020 | 0.82 | HCAR3 (0.44) | HCAR3LMNAMAPTALDH1A1KAT2B | |
| SCHEMBL13206384 | 0.79 | LMNA (0.61) | HCAR3LMNAMAPTL3MBTL1MAPK1 | |
| SCHEMBL9428302 | 0.79 | HCAR3 (0.48) | HCAR3LMNAMAPTL3MBTL1MAPK1 | |
| SCHEMBL29669390 | 0.78 | HCAR3 (0.45) | HCAR3LMNAMAPTL3MBTL1MAPK1 | |
| SCHEMBL28995911 | 0.75 | MAPT (0.41) | HCAR3LMNAMAPTL3MBTL1MAPK1 | |
| SCHEMBL2060849 | 0.75 | HCAR3 (0.48) | HCAR3LMNAMAPTL3MBTL1MAPK1 | |
| SCHEMBL3512219 | 0.74 | MAPT (0.57) | HCAR3LMNAMAPTL3MBTL1MAPK1 | |
| SCHEMBL31481963 | 0.74 | MAPT (0.57) | HCAR3LMNAMAPTL3MBTL1MAPK1 | |
| SCHEMBL4428318 | 0.74 | HCAR3 (0.61) | HCAR3LMNAMAPTL3MBTL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KINNATE BIOPHARMA INC. | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | FGFR1, FGFR2, FGFR3 | HCAR3 2136/4885LMNA 2611/4885MAPT 3513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.